新型免疫抑制剂麦考酚酸酯

　　［5］Carr SF, Pappe E, Wu JC. Characterization of human type I and type II IMP dehydrogenase［J］. J Biol Chem 1993; 268: 27286-90.

　　［6］Langman LT, LeGatt DF, Yarscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity［J］. Clin Chem 1995; 41: 295-9.

　　［7］Langman LJ, Shapiro AMJ, Lakey JRT. Pharmacodynamic assessment of MPA-induced immunosuppression by measurement of IMP dehydrogenase activity in a canine model［J］. transplantation 1996; 61: 87-92.

　　［8］Franklin TJ, Morris WP. Pharmacodynamics of the inhibition of GTP synthesis in vitro by mycophenolic acid［J］. Adv Enzyme Regul 1994; 34:107-17.

　　［9］Nage SE, Andersson JP, Andersson UG. Effect of mycophenolate mofetil on cytokine production inhibition of superantigen-induced cytokines［J］. immunopharmacology 1993; 26: 11-20.

　　［10］Bullingham R, Monroe S, Nicholls A. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration［J］. J Clin Pharmacol 1996; 36: 315-24.

　　［11］Sugioka N, Chen SH, Hayashida K. Stability and pharmacokinetic studies of a new immunosuppressant mycophenolate mofetil (RS-61443) in rats［J］. biopharm Drug Dispos 1995; 16: 591-601.

　　［12］Sollinger HW, Deierhoi MH, Belzer FO. RS-61443-a phase I clinical trial and pilot rescue study［J］. Transplantation 1992; 53: 428-32.

　　［13］European Mycophenolate mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection［J］. Lancet 1

　　［14］Sollinger HW, US Renal Transplant Mycophenolate mofetil Study Group. mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients［J］. Transplantation 1995; 60: 225-32.

　　［15］The Tricontinental Mycophenolate mofetil Renal Tra

上一页  [1] [2] [3] [4] 下一页